demonstrated that pre-infusion elevations in serum ferritin, C-reactive protein, and interleukin-6 were significantly correlated with reduced overall survival in patients with relapsed or refractory multiple myeloma undergoing CAR T-cell therapy (59). The gene discussed is CRP; the disease is plasma cell myeloma.